DPCO 2013: A fair move or a misstep?
The DPCO 2013 issued by the DOP covers the prices of 652 formulations in over 27 therapeutics. Usha Sharma talks to industry…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
’Drug price controls aren’t the only solution’
Any move that makes healthcare affordable for patients is welcome, but drug price controls aren’t the only solution. The…
’Adverse impact of DPCO will be significant on OPPI member companies’
Immediate adverse impact of DPCO 2013, on both sales and margins, will be quite significant to OPPI member companies. However, a…
‘The paradigm shift from cost-based pricing to market-based pricing has been long…
India’s search for a universal formula to fix prices of essential drugs appears to have been addressed with the new pharma policy…
‘A win-win policy for all stakeholders’
DPCO 2013 is truly a win-win move for the patient, pharma industry and the Government. Indian pharma industry generates…
’DPCO 2013 will equally affect domestic as well multinational pharma companies’
.custom-style{font-family: tahoma,arial,helvetica,sans-serif; font-size: small;}
The DPCO 2013 aims to put in place a regulatory…
’Longer-term growth prospects’
ICRA expects that the latest proposed market-based pricing mechanism for the Indian pharma industry would impact near term…
‘This pricing policy would help on affordability issue’
The impact on the pharma industry revenues will be limited for around 12-18 months, post which the product portfolio will evolve…
‘It would be too early to call this policy a boon or bane’
The NELM policy is adopted to strike a balance between the growing pharma industry of the nation and offer accessibility and…
‘Government should also focus on affordability and access’
Whilst the move to market-based pricing is positive, the Government must focus on the real issue which is affordability and access…